Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease
Authors' conclusion
KidneyIntelX was associated with targeted GDMT usage with favourable changes in kidney and metabolic clinical measures and risk trajectories, with lower risk linked to therapy initiation and reduction in biomarkers.
Study context
- Population
- Adults with T2D and CKD (G1-G3b) from two medical centres; median baseline eGFR 63 mL/min/1.73 m², UACR 51 mg/g, HbA1c 7.2%
- Participants
- 2,470 adults
- Exposure
- KidneyIntelX high and intermediate vs low risk strata
- Outcome
- Kidney composite outcome of:
- Sustained eGFR decline of 40%
- Kidney failure by baseline KidneyIntelX risk strata
Methodological detailstwo medical centres
- Two medical centres
Main finding
As reported in the abstract
Diabetic kidney disease (DKD) progression (kidney composite outcome)
Each group vs lowHazard ratio (CI)
High
10.4(4.4–24.8)
Intermediate
4.0(2.0–8.7)
Observational data: associations, not effects.
Further findings
Baseline KidneyIntelX risk distribution · median baseline
SGLT2i usage post-test
SGLT2i combined with GLP-1 usage post-test, by risk group
- SGLT2i combined with GLP-1 increased per risk group (high, intermediate, low respectively)
- 32%, 25%, 17%
Kidney and metabolic trajectories after testing, high-risk group
- Improvement in eGFR slope, greatest in high-risk group
- −4.6 to −2.6 mL/min/1.73 m²/year
- UACR relative decrease, greatest in high-risk group
- 23%
- HbA1c relative decrease, greatest in high-risk group
- 7.6%
Risk at repeat testing · 12-month
- Repeat-tested participants
- 1143
- Transitioned to lower risk, accompanied by biomarker reductions, specifically KIM-1
- 29%
- Initiation of SGLT2i or GLP-1 doubled odds of risk reduction
Original publication
Real‐World Associations of KidneyIntelX Risk Stratification With Guideline‐Directed Therapy, Kidney Outcomes, and Metabolic Trajectories in Early Diabetic Kidney Disease. Diabetes Obes Metab. Published 28 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →